Rohto PharmaceuticalLtd's CEO is Hidetoshi Segi, appointed in Jun 2025, has a tenure of 1.17 years. directly owns 0.005% of the company’s shares, worth $199.92K. The average tenure of the management team and the board of directors is 2.2 years and 5.2 years respectively.
Key information
Hidetoshi Segi
Chief executive officer
n/a
Total compensation
CEO salary percentage
n/a
CEO tenure
1.2yrs
CEO ownership
0.005%
Management average tenure
2.2yrs
Board average tenure
5.2yrs
Recent management updates
Recent updates
CEO
Hidetoshi Segi (64 yo)
1.2yrs
Tenure
Mr. Hidetoshi Segi is Chief Operating Officer at Rohto Pharmaceutical Co.,Ltd since June 2025. Mr. Segi served as Chief Strategy Officer for Rohto Pharmaceutical Co.,Ltd since March 2022 until June 2025 an...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Hidetoshi Segi
COO, President & Representative Director
1.2yrs
no data
0.0049% $ 199.9k
Saito Masaya
Executive VP
4.4yrs
no data
0.021% $ 871.9k
Shinichi Kunisaki
Executive VP
4.4yrs
no data
0.019% $ 781.2k
Yoichi Honma
Chief Scientific Officer & Director
2.2yrs
no data
no data
Hideto Kamimura
Senior Executive Officer and General Manager of Marketing Division
no data
no data
0.0053% $ 218.0k
Yasunori Kawasaki
Chief Human Resources Officer & Director
3.2yrs
no data
no data
Masae Yamanaka
Chief Transformation Officer & Director
2.2yrs
no data
no data
Noriko Suenobe
Chief Research Officer & Director
1.2yrs
no data
no data
Yoko Fujimoto
MD, Chief Medical Officer & Director
1.2yrs
no data
no data
2.2yrs
Average Tenure
63yo
Average Age
Experienced Management: RPHC.F's management team is considered experienced (2.2 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Hidetoshi Segi
COO, President & Representative Director
8.2yrs
no data
0.0049% $ 199.9k
Saito Masaya
Executive VP
15.2yrs
no data
0.021% $ 871.9k
Shinichi Kunisaki
Executive VP
16.2yrs
no data
0.019% $ 781.2k
Yoichi Honma
Chief Scientific Officer & Director
2.2yrs
no data
no data
Yasunori Kawasaki
Chief Human Resources Officer & Director
3.2yrs
no data
no data
Masae Yamanaka
Chief Transformation Officer & Director
2.2yrs
no data
no data
Noriko Suenobe
Chief Research Officer & Director
1.2yrs
no data
no data
Yoko Fujimoto
MD, Chief Medical Officer & Director
1.2yrs
no data
no data
Yamada Kunio
Chairman of the Board
27.2yrs
JP¥208.00m
0.52% $ 21.4m
Akie Iriyama
Independent Outside Director
7.2yrs
no data
no data
Haruka Mera
Independent Outside Director
6.2yrs
no data
no data
Eriko Hayashi
Independent Outside director
4.2yrs
no data
no data
5.2yrs
Average Tenure
62yo
Average Age
Experienced Board: RPHC.F's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/08 10:11
End of Day Share Price
2026/05/14 00:00
Earnings
2026/06/30
Annual Earnings
2026/03/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rohto Pharmaceutical Co.,Ltd. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.